Mepolizumab - GlaxoSmithKline

Drug Profile

Mepolizumab - GlaxoSmithKline

Alternative Names: 240563; Bosatria; Mepolizamab; Nucala; SB-240563

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; McMaster University; National Institute of Allergy and Infectious Diseases
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypereosinophilic syndrome; Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Registered Churg-Strauss syndrome
  • Preregistration Chronic obstructive pulmonary disease
  • Phase III Hypereosinophilic syndrome; Nasal polyps
  • Phase II Atopic dermatitis
  • No development reported Eosinophilic oesophagitis

Most Recent Events

  • 10 Sep 2018 Pooled efficacy data from clinical trials in Asthma released by GlaxoSmithKline
  • 07 Sep 2018 GlaxoSmithKline receives complete response letter from the US FDA for mepolizumab in Chronic obstructive pulmonary disease (COPD)
  • 30 Aug 2018 Registered for Asthma (Adjunctive treatment, In adolescents, In children) in European Union, Norway, Liechtenstein and Iceland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top